Patents Assigned to Merck Sharp & Dohme
  • Anti-coagulation factor XI antibodies
    Patent number: 11485794
    Abstract: Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: November 1, 2022
    Assignees: Merck Sharp & Dohme LLC, Adimab, LLC
    Inventors: Zhu Chen, Kenneth Ellsworth, James Milligan, Elizabeth Oldham, Dietmar Seiffert, Bianka Prinz
  • PCSK9 antagonist compounds
    Patent number: 11484565
    Abstract: Disclosed are compounds of Formula A, or a pharmaceutically acceptable salt thereof: where A, X, R1, and R2 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.
    Type: Grant
    Filed: August 28, 2020
    Date of Patent: November 1, 2022
    Assignee: MERCK SHARP & DOHME LLC
    Inventors: Hubert Josien, Abbas Walji, Harold B. Wood, Fa-Xiang Ding, Jian Liu, Thomas Joseph Tucker, Michael Man-Chu Lo, Liangqin Guo
  • BIOMARKERS FOR ANTI-TIGIT ANTIBODY TREATMENT
    Publication number: 20220340660
    Abstract: Novel methods for selecting a patient with a cancer for treatment with a TIGIT antagonist are disclosed. The methods employ various biomarkers, including CD45, CD3?, CD11b, Foxp3, IFN-?, Cxcl11, Cxcl10, TNF-?, IL-23, MHC class II, CD80, CD86, and CD40.
    Type: Application
    Filed: October 1, 2019
    Publication date: October 27, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Sybil M.G. Williams, Jin-Hwan Han, Drake Maurice LaFace, Elaine Pinheiro, Wolfgang Seghezzi
  • [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors
    Patent number: 11478461
    Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: October 25, 2022
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Liangqin Guo, Hongjun Zhang, Ping Chen, Dane Clausen, Xavier Fradera, Yongxin Han, Shuwen He, Xianhai Huang, Alexander Pasternak, Qinglin Pu, Li Xiao, Feng Ye
  • Anti-coagulation factor XI antibodies
    Patent number: 11479615
    Abstract: Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: October 25, 2022
    Assignees: Merck Sharp & Dohme LLC, Adimab, LLC
    Inventors: Zhu Chen, Kenneth Ellsworth, James Milligan, Elizabeth Oldham, Dietmar Seiffert, Bianka Prinz
  • Compounds, compositions and methods
    Patent number: 11479542
    Abstract: The disclosed subject matter provides certain polymorphic forms of Compound (I) as well as pharmaceutical compositions comprising Compound (I) or such polymorphic forms, and methods of using or making such compounds and pharmaceutical compositions. It has now been discovered that Compound (I) can exist in multiple crystalline forms (polymorphs). One particular crystalline form, Form II, has been found to be more thermodynamically stable and, thus, likely more suitable for bulk preparation and handling than other polymorphic forms. Efficient and economic methods have been developed to prepare Compound (I) and Form II in high purity on a large scale. In animal studies, Form II has demonstrated safety and efficacy in treating depressive disorders and, when micronized, improved absorption compared to non-micronized Form II.
    Type: Grant
    Filed: May 27, 2020
    Date of Patent: October 25, 2022
    Assignees: CERECOR, INC., MERCK SHARP & DOHME CORP.
    Inventors: Reza Mazhari, Djelila Mezaache, Blake M. Paterson, James Vornov, Rachel M. Garner, Todd Nelson
  • METHODS FOR TREATMENT AND PROPHYLAXIS OF HIV AND AIDS
    Publication number: 20220331350
    Abstract: The present invention is directed to methods for inhibition of HIV reverse transcriptase, treatment of infection by HIV, prophylaxis of infection by HIV, and the treatment, prophylaxis and/or delay in the onset or progression of AIDS or ARC by administering a compound of structural Formula I or a pharmaceutically acceptable salt or co-crystal thereof, wherein X is —F or —Cl, less frequently than once daily.
    Type: Application
    Filed: April 8, 2022
    Publication date: October 20, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Daria Hazuda, Michael D. Miller, Jay A. Grobler, Deborah Anne Nicoll-Griffith
  • ANTIMALARIAL AGENTS
    Publication number: 20220331321
    Abstract: Methods of treating malaria comprising administration of compounds of Formula (I?) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. It also provides uses of the compounds of Formula (I), as defined herein, for inhibiting plasmepsin X, plasmepsin IX or plasmepsin X and IX activity, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.
    Type: Application
    Filed: July 21, 2020
    Publication date: October 20, 2022
    Applicants: Merck Sharp & Dohme Corp., The Walter and Eliza Hall Institute of Medical Research, MSD R & D (China) Co. LTD.
    Inventors: John A. McCauley, Alan F. Cowman, Manuel de Lera Ruiz, Paola Favuzza, Zhuyan Guo, Bin Hu, Michael J. Kelly, III, Zhiyu Lei, David B. Olsen, Brad Sleebs, Jennifer K. Thompson, Tony Triglia, Dongmei Zhan, Cailing Zhang, Lianyun Zhao
  • Apparatus and Method for Monitoring and Recording Disintegration Times for Pharmaceutical Products
    Publication number: 20220334040
    Abstract: Embodiments of the present invention provide an apparatus and method for determining whether a dosage unit of a pharmaceutical dmg disintegrates in an immersion fluid of a disintegration tester within a prescribed time limit and to record and transmit to human-accessible output devices the times required. In one implementation, the apparatus comprises a computer system, a motion sensor, a capture device, a fastener for attaching the capture device and motion sensor to the reciprocating arm of the disintegration tester, and one or more data communications interfaces to carry commands and data between the computer system, the motion sensor and the capture device.
    Type: Application
    Filed: September 29, 2020
    Publication date: October 20, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Grace Chen, Joanna C. Everitt, Sydney Floryanzia, Janakiraman Gopinath, Prashant I. Shah
  • Pharmaceutical compositions of a peptide
    Patent number: 11471512
    Abstract: Disclosed are pharmaceutical compositions comprising the peptide of SEQ ID No. 1, or a pharmaceutically acceptable salt or counterion thereof, methods of preparing such pharmaceutical compositions, and methods of treating diabetes and diabetes-related disorders with such pharmaceutical compositions.
    Type: Grant
    Filed: February 26, 2020
    Date of Patent: October 18, 2022
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Himanshu Bhattacharjee, Suzanne M. D'Addio, Sachin Lohani, Sachin Mittal, Sergei Y. Pechenov, Daniel Hong Yin
  • PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC POLYSACCHARIDE-CARRIER PROTEIN CONJUGATES
    Publication number: 20220323564
    Abstract: The present invention provides capsular polysaccharides from Streptococcus pneumoniae serotypes identified using NMR. The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additional Streptococcus pneumoniae serotypes.
    Type: Application
    Filed: June 24, 2022
    Publication date: October 13, 2022
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Richard J. Porambo, Chitrananda Abeygunawardana, Luwy Kavuka Musey, Michael J. Kosinski, Yadong Adam Cui
  • COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR INHIBITOR FOR TREATING CANCER
    Publication number: 20220324979
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a VEGFR inhibitor, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that express PD-L1.
    Type: Application
    Filed: April 20, 2022
    Publication date: October 13, 2022
    Applicants: PFIZER INC., MERCK SHARP & DOHME CORP.
    Inventors: Jean-Francois Andre MARTINI, Jamal Christo Tarazi, Rodolfo Fleury Perini, David J. Mauro
  • PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC POLYSACCHARIDE-CARRIER PROTEIN CONJUGATES
    Publication number: 20220323592
    Abstract: The present invention provides capsular polysaccharides from Streptococcus pneumoniae serotypes identified using NMR. The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additional Streptococcus pneumoniae serotypes.
    Type: Application
    Filed: June 24, 2022
    Publication date: October 13, 2022
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Richard J. Porambo, Chitrananda Abeygunawardana, Luwy Kavuka Musey, Michael J. Kosinski, Yadong Adam Cui
  • PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC POLYSACCHARIDE-CARRIER PROTEIN CONJUGATES
    Publication number: 20220323565
    Abstract: The present invention provides capsular polysaccharides from Streptococcus pneumoniae serotypes identified using NMR. The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additional Streptococcus pneumoniae serotypes.
    Type: Application
    Filed: June 24, 2022
    Publication date: October 13, 2022
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Richard J. Porambo, Chitrananda Abeygunawardana, Luwy Kavuka Musey, Michael J. Kosinski, Yadong Adam Cui
  • PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC POLYSACCHARIDE-CARRIER PROTEIN CONJUGATES
    Publication number: 20220323593
    Abstract: The present invention provides capsular polysaccharides from Streptococcus pneumoniae serotypes identified using NMR. The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additional Steptococcus pneumoniae serotypes.
    Type: Application
    Filed: June 24, 2022
    Publication date: October 13, 2022
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Richard J. Porambo, Chitrananda Abeygunawardana, Luwy Kavuka Musey, Michael J. Kosinski, Yadong Adam Cui
  • Cyclic di-nucleotide compounds as sting agonists
    Patent number: 11466047
    Abstract: A class of polycyclic compounds of general formula (I), wherein Base1, Base2, Y, Ya, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2, R2a, R3, R4, R4a, R5, R6, R6a, R7, R7a, R8, R8a, and R9 are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds.
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: October 11, 2022
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Wen-Lian Wu, Jongwon Lim, Jared N. Cumming, Benjamin Wesley Trotter, Wonsuk Chang
  • PRO DRUGS OF PDE10 COMPOUNDS
    Publication number: 20220306619
    Abstract: The present invention is directed to pro drugs of 2-methyl-N-((5-methyl-1,3,4-thiadiazol-2-yl)methyl)-6-(((1S,2S)-2-(5-methylpyridin-2-yl)cyclopropyl)methoxy)pyrimidin-4-amine which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
    Type: Application
    Filed: March 15, 2022
    Publication date: September 29, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Sachin Mittal, Jason W. Skudlarek, Izzat T. Raheem
  • HYDROXYPYRROLIDINE-SUBSTITUTED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS
    Publication number: 20220305035
    Abstract: Disclosed are compounds of Formula A, or a salt thereof: Wherein “A1”, R1, R2, R3, R6, and R7 are as defined herein, which compounds have properties for blocking Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A or their salts, and methods of treating cough, itch and neuropathic pain disorders using the same.
    Type: Application
    Filed: June 8, 2020
    Publication date: September 29, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Anthony J. Roecker, Mark E. Layton, Deping Wang, Xiu Wang, Xuanjia Peng
  • Cyclic di-nucleotide compounds as sting agonists
    Patent number: 11453697
    Abstract: A class of polycyclic compounds of general formula (I), of general formula (I?), or of general formula (I?), wherein Base1, Base2, Y, Ya, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2, R2a, R3, R4, R4a, R5, R6, R6a, R7, R7a, R8, and R8a are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds.
    Type: Grant
    Filed: June 18, 2020
    Date of Patent: September 27, 2022
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Michael D. Altman, Brian Andresen, Wonsuk Chang, Jared N. Cumming, Ryan D. Otte, Benjamin Wesley Trotter
  • Pharmaceutical compositions of tedizolid phosphate
    Patent number: 11452719
    Abstract: Disclosed are pharmaceutical compositions comprising tedizolid phosphate, methods of preparing such pharmaceutical compositions, and methods of treating bacterial infections with such pharmaceutical compositions. Specifically, a pharmaceutical composition comprising tedizolid phosphate, an acid; and a suspending agent; and wherein the pH of the composition upon constitution with water is between about pH 2-4.5, is provided, wherein the acid is not citric acid or malic acid.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: September 27, 2022
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Lixia Cai, David Dubost, David Harris, Yongjun Li, Majid Mahjour, Dan Zhang